Mogrify

Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.

In a collaboration with Sangamo, Mogrif’s cell conversion technology will be applied to generate regulatory T cells (Tregs) from pluripotent stem cells and embryonic stem cells. Sangamo aims to apply its ZFP gene engineering technology to Tregs as allogeneic cell therapies to treat inflammatory and autoimmune diseases.